论文部分内容阅读
琦玉县癌中心米田修一医师等的研究小组,开发了一种“导弹疗法”治疗肺小细胞癌。它是利用单克隆抗体仅对肺小细胞癌有极好的集结特性,将~(131)Ⅰ附着到称为“TFS—4”的单克隆抗体上,投给患者,以攻击病灶。抗癌剂与单克隆抗体结合的导弹疗法,以往对恶性黑色素瘤作过尝试,但以放射性物质作为弹头这还是第一次。米田医师在东京大学医学部的协助下,使用移植了人的肺小细胞癌的小白鼠研究其疗效。结果,半个月后癌肿缩小到原来的60%,而不集结于肺小细胞癌的抗体实验时,在同一期间内癌的大小则增大到原来的3～4倍。
At the Saitama Cancer Center, Miyoshi Aichi and other doctors have developed a “missile therapy” for small cell lung cancer. It uses monoclonal antibodies that have excellent agglutination properties only for small cell lung cancer and attach ~(131)I to a monoclonal antibody called “TFS-4” to be administered to patients to attack the lesion. The missile therapy, which combines anticancer agents with monoclonal antibodies, has previously attempted malignant melanoma, but this is the first time that radioactive materials have been used as warheads. Dr. Miyada studied the efficacy of mice transplanted with human small cell lung cancer with the assistance of the University of Tokyo Medical School. As a result, the cancer was reduced to 60% in the first half of the month. When the antibody was not collected in small cell lung cancer, the size of the cancer increased to 3 to 4 times in the same period.